
Quick Q&A: Sarah Klein on scrutinizing PBM contracts
Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.
Sarah Klein is senior vice president and director of pharma and PBM consulting at Lockton. At the 2026 Pharmacy Benefit Management Institute (PBMI) Annual National Conference, she spoke with Managed Healthcare Executive about how new transparency and passthrough rules are affecting Lockton's analysis of pharmacy benefit manager (PBM) business proposals now and in the years ahead. (See more of
"Employers are starting to ask the hard questions now," Klein said, even though much of the new regulation is not yet in effect. As Lockton reviews PBM proposals, she said, the firm is trying to understand what transparency means for each PBM and how to communicate that to its employer and health plan clients.
Klein is also looking further down the road. In requests for proposals (RFPs) being run now for next year, 2029 is the third year of the contract term, she said. That means Lockton is already thinking about what will change during the contract it is evaluating today.
A central part of that analysis is the reservation of rights that PBMs build into their contracts, which allows them to change their guarantees or the entire structure of their pricing. Klein says Lockton wants to know what will trigger those changes. Beyond the triggers, she said, the firm wants to know what kind of analysis the PBM will show the client to prove that the arrangement is economically stable in 2029.
For employers and health plans, those questions shift the focus of a PBM evaluation from the first-year price to how the deal is likely to hold up as new rules take effect.
In this video, Klein discusses how transparency rules are changing the questions Lockton asks of PBMs and what it looks for in contract terms that extend into 2029.
Related to this article








